- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05734794
Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial (STORM)
August 23, 2023 updated by: Mao Jianhua, The Children's Hospital of Zhejiang University School of Medicine
Study of Rituximab Monotherapy VS Steroid Therapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial
The main objective is to evaluate the effectiveness of Rituximab monotherapy versus steroid therapy on children with new-onset nephrotic syndrome within the 52-week follow-up.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Nephrotic syndrome(NS) -------the most common glomerular disease in children.
Steroid, as the mainstream therapy for decades, many patients suffer from adverse effects of it, such as growth impacted, fat, and glaucoma.There is a urgent need for Steroid-sparing therapy.
Rituximab, as a chemical monoclonal antibody against the cluster of differentiation antigen 20(CD20), has proved to be effective in patients with frequent-relapse/steroid-dependent NS.
It has also been reported to be effective in six adult patients with new-onset NS.
Rituximab mono-therapy in new-onset pediatric NS patients is still unclear.
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianhua Mao, PHD.MD
- Phone Number: 86057186670015
- Email: maojh88@zju.edu.cn
Study Contact Backup
- Name: Fei Liu
- Email: alexdevin@163.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Children's Hospital, Zhejiang University School of Medicine
-
Contact:
- Li Qiu-Yu
- Phone Number: 17794588355
- Email: liqiuyu1992@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- New-onset idiopathic nephrotic syndrome
- Glomerular filtration rate (eGFR) ≥90 ml/min per 1.73 m2 at study entry.
Exclusion Criteria:
- Glomerular hematuria: Urine red blood cell counts≥ 10/high power field(HP), ≥ 3 times within 2 weeks;
- Continuous hypocomplementaemia(< 0.9g/L) ;
- Repeated or persistent Hypertension(systolic and/or diastolic blood pressures measured greater than the 95th percent of blood pressure in children matching sex, age and height ≥3 different time points)
- Diagnosis of secondary NS, such as secondary to Systemic Lupus Erythematosus, Immunoglobulin A Vasculitis(IgAV), diabetes, Hepatitis B virus(HBV) infection, etc.
- Complicated with other kidney diseases, such as multiple renal cysts, ANCA vasculitis, urinary system abnormalities, etc;
- With a family history of nephrotic syndrome, chronic glomerulonephritis, uremia, or other kidney diseases;
- Other monogenic genetic diseases known as the effect the condition of nephrotic syndromes, such as Wilms' tumor 1(WT1), NPHS2, LAMB2, PLCE1, etc.
- Congenital or acquired immunodeficiency, or patients with active tuberculosis, active Epstein-Barr virus and cytomegalovirus(CMV), acute hepatitis B, hepatitis C, HIV infection, deep fungal infection or other active infections.
- Laboratory indicators were abnormal, such as moderate or severe neutropenia(≤1000/μL), moderate or severe anemia(hemoglobin<9.0g/dL), Thrombocytopenia (platelet count<100* 10^12/L) or with abnormal hepatic function (Alaninetransaminase(ALT), aspartate Aminotransferase(AST) or bilirubin >2.5*upper limit of normal value and continue to increase for 2 weeks);
- Steroid or immunosuppressive medicine for other diseases within 3 months, such as cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil, tripterygium wilfordii, etc.
- With tumor, severe cardiac failure, severe hepatologic diseases, hematological diseases, or other severe system diseases.
- Patients who are known to be allergic to rituximab;
- History of transplantation, excluding cornea or hair transplantation;
- The attenuated live vaccine was inoculated within 1 month before enrollment;
- Patients who participated in other clinical trials within three months before enrollment;
- Patients are not suitable for inclusion in the trial by any investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rituximab Group
Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days).
|
Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week.
If the patient is not allergic) for three months from the first rituximab dosing date(Day 1).
Four doses of rituximab are necessary whether the patient achieves complete remission.
|
Active Comparator: Steroid Group
Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks.
|
Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks.
Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence-free survival time(day) after first complete remission
Time Frame: From complete remission to 52 weeks
|
The time from complete remission to the first relapse during the whole 52-week follow-up in patients who achieve complete remission within 6 weeks.
In order to evaluate the remission, all the participants will document their proteinuria.
Relapse is defined by first-morning urine dipstick ≥3+ on three or more consecutive days, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg, with or without edema after complete remission(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).
Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).
|
From complete remission to 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete remission of nephrotic syndrome
Time Frame: From admission day to 6 weeks
|
Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions (KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).
It will be recorded as "1" when patients achieve complete remission, or as "0".
|
From admission day to 6 weeks
|
Inefficiency of nephrotic syndrome
Time Frame: From admission day to 6 weeks
|
Inefficiency is defined as patients still have nephrotic-range proteinuria(first-morning urine dipstick ≥3+dipstick, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg) after 6-week treatment.
|
From admission day to 6 weeks
|
The time(day) to first complete remission
Time Frame: From admission day to 6 weeks
|
The time(day) from the first medicine administration to complete remission within 6 weeks.Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions (KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).
|
From admission day to 6 weeks
|
Relapse of nephrotic syndrome
Time Frame: From admission day to 52 weeks
|
Relapse is defined as patients who have first-morning urine dipstick ≥3+ on three or more consecutive days, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg, with or without edema after complete remission(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).
It will be recorded as "1" when patients have a relapse, or as "0".
|
From admission day to 52 weeks
|
Cumulative prednisone dosage of each individual (milligrams per kilogram per year)
Time Frame: From admission day to 52 weeks
|
The total dosage of prednisone for each individual from the beginning to the end of the trial.
|
From admission day to 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013 Nov;84(5):1025-33. doi: 10.1038/ki.2013.211. Epub 2013 Jun 5.
- Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003 Aug 23;362(9384):629-39. doi: 10.1016/S0140-6736(03)14184-0.
- Veltkamp F, Rensma LR, Bouts AHM; LEARNS consortium. Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis. Pediatrics. 2021 Jul;148(1):e2020029249. doi: 10.1542/peds.2020-029249. Epub 2021 Jun 30.
- Filler G, Young E, Geier P, Carpenter B, Drukker A, Feber J. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis. 2003 Dec;42(6):1107-13. doi: 10.1053/j.ajkd.2003.08.010.
- Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997 May;8(5):769-76. doi: 10.1681/ASN.V85769.
- Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018 Jul 7;392(10141):61-74. doi: 10.1016/S0140-6736(18)30536-1. Epub 2018 Jun 14. Erratum In: Lancet. 2018 Jul 28;392(10144):282.
- Ye Q, Mao JH. [Immunologic pathogenesis of idiopathic nephrotic syndrome in children: the present and future]. Zhonghua Er Ke Za Zhi. 2020 Sep 2;58(9):705-707. doi: 10.3760/cma.j.cn112140-20200626-00664. Chinese.
- Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017 Apr;21(2):193-202. doi: 10.1007/s10157-016-1313-5. Epub 2016 Jul 15.
- Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol. 2013 Mar;9(3):154-69. doi: 10.1038/nrneph.2012.289. Epub 2013 Jan 22.
- Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K, Kamei K, Kemper MJ, Ma AL, Parekh RS, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Yap HK, Tullus K. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study. J Am Soc Nephrol. 2022 Jun;33(6):1193-1207. doi: 10.1681/ASN.2021111472. Epub 2022 Mar 30.
- Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, Menegatti E, Roccatello D. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018 Jun 22;9(48):28799-28804. doi: 10.18632/oncotarget.25612. eCollection 2018 Jun 22.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 9, 2023
Primary Completion (Estimated)
December 25, 2025
Study Completion (Estimated)
July 30, 2026
Study Registration Dates
First Submitted
November 20, 2022
First Submitted That Met QC Criteria
February 9, 2023
First Posted (Actual)
February 21, 2023
Study Record Updates
Last Update Posted (Actual)
August 25, 2023
Last Update Submitted That Met QC Criteria
August 23, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Syndrome
- Nephrotic Syndrome
- Nephrosis
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- STORM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rituximab
-
University of GiessenNovartis; Astellas Pharma US, Inc.; German Cancer Research Center; Heidelberg UniversityCompletedKidney Transplantation | Immunology | Virus | Living Donors | Rituximab (RTx)Germany
-
The Affiliated Hospital of Qingdao UniversityNot yet recruitingChildren | Blood Disease | Rituximab
-
Arbeitsgemeinschaft medikamentoese TumortherapieCompletedFollicular T-NHL Lymphoma | Rituximab Maintenance
-
Zhejiang Cancer HospitalRecruitingRituximab, Lenalidomide, Zebutinib ,Mantle Cell LymphomaChina
-
Sun Yat-sen UniversityRecruitingLymphoma, Non-Hodgkin | Pediatric Cancer | RituximabChina
-
Samsung Medical CenterCompletedPatients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma | Patients Treated With Rituximab-CHOP or Rituximab-CVPKorea, Republic of, Malaysia, Singapore, China
-
University Hospital Inselspital, BerneRecruitingImmunosuppression | Rituximab | COVID19 VaccinationSwitzerland
-
Cancer Institute and Hospital, Chinese Academy...UnknownDiffuse Large B-cell Lymphoma | Rituximab | ToripalimabChina
-
Fudan UniversityUnknownNeoplasms | Immune System Diseases | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Gemcitabine | Cisplatin | Dexamethasone | Rituximab | Cyclophosphamide | Chidamide | Neoplasm by Histology | HDAC InhibitorChina
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruitingRefractory Myasthenia Gravis | RituximabChina
Clinical Trials on Steroid
-
Services Hospital, LahoreArmed Forces Institute of Urology, RawalpindiCompleted
-
University Hospitals Coventry and Warwickshire...University Hospital, GenevaTerminatedTopical Corticosteroid-treated Dermatology Patients | Intra-ocular PressureUnited Kingdom
-
Johns Hopkins UniversityWithdrawn
-
Blackpool Teaching Hospitals NHS Foundation TrustNot yet recruitingShoulder Subacromial Pain SyndromeUnited Kingdom
-
Istanbul Medeniyet UniversityMarmara UniversityRecruitingLumbosacral RadiculopathyTurkey
-
Franklin Pierce UniversityUniversity of Colorado, DenverCompletedLumbar Spinal StenosisUnited States
-
Peking Union Medical College HospitalCompletedCovid19 | ARDS: Acute Respiratory Distress SyndromeChina
-
Beijing Tongren HospitalFirst Affiliated Hospital, Sun Yat-Sen University; China-Japan Union Hospital...Active, not recruitingSinusitis | Nasal Polyps | PatientsChina
-
University of RochesterTerminatedChronic Rhinosinusitis (Diagnosis)United States